Mylan 1st-qtr 2014 revenues miss analysts’ expectations

US generic drugmaker Mylan (Nasdaq: MYL) reported first-quarter 2014 results before markets opened, posting adjusted diluted earnings per share (EPS) of $0.66 on revenues of $1.72 billion, up from adjusted EPS of $0.62 on revenues of $1.63 billion in the like 2013 quarter, and compares to the Thomson Reuters consensus estimates for EPS of $0.64 and $1.78 billion in revenues.

Mylan chief executive Heather Bresch commented: "Mylan's performance during the first quarter slightly exceeded our expectations and marked a great start to what we believe will be another good year. Our operations in India drove strong top-line growth as a result of increased sales from our antiretroviral franchise. Additionally, the diversity and strength of our product portfolio in North America demonstrated our ability to continue to leverage our operating platform.”

Reaffirms full-year guidance